Compare iShares Silver Trust (SLV) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Silver Trust vs Tango Therapeutics Inc. — how do they compare? iShares Silver Trust trades at $51.25 (market cap $28.90B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: iShares Silver Trust is far larger — about 7.7× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Silver Trust for 90 Days and Tango Therapeutics Inc. for 0 Days on average.
| SLV | TNGX | |
|---|---|---|
Market Cap | $28.90B | $3.74B |
Volume | 36,248,796 | 3,438,781 |
52-Week High | $105.57 | $32.90 |
52-Week Low | $42.40 | $7.50 |
Typical Hold Time | 90 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLV, the iShares Silver Trust ETF, is trading at $50.22, down 7.6% over 24 hours amid a bearish technical signal. The trust holds substantial assets of $13.41 billion with minimal liabilities, but financial metrics like P/E and revenue are unavailable. Recent news highlights pressure from rising Treasury yields and a stronger dollar, contributing to silver's sharp decline.
The outlook remains cautious due to macroeconomic headwinds and Fed policy uncertainty. While silver's industrial and monetary appeal offers long-term potential, near-term volatility and bearish technical indicators suggest limited upside. Risks include interest rate sensitivity and market sentiment shifts, requiring careful monitoring for entry points.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
